SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is currently seeing volatile trading as investors weigh concerns over Medicare Advantage reimbursement rates and regulatory pressures against the company's long-term potential as a defensive sector leader. The community is actively debating whether current price levels represent a significant buying opportunity ahead of upcoming policy decisions, with many participants closely monitoring institutional positioning and sector-wide sentiment.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is experiencing significant market volatility and high trading volume as investors react to a transformational earnings report featuring robust revenue guidance and the integration of its recent acquisition. The community is actively debating the timing of potential major contract awards, with bullish sentiment driven by the company's ambitious 2026 outlook and its unique position in lunar infrastructure, while short sellers remain focused on execution risks and past delays.

Satellogic, Inc. operates as a vertically integrated geospatial company. It is creating and continuously enhancing the first scalable, fully automated EO platform with the ability to remap the entire planet at both high-frequency and high-resolution, providing accessible and affordable solutions for customers. The company was founded by Emiliano Kargieman and Gerardo Richarte in July 2010 and is headquartered in Davidson, NC.

Satellogic Inc - Ordinary Shares - Class A

Satellogic is currently seeing significant momentum and high volume as investors react to the company's recent registered direct offering and ongoing expansion of its global satellite monitoring capabilities. The community is actively discussing the stock's potential for a broader rally, with many highlighting its strategic defense sector partnerships and speculative appeal as a potential acquisition target or long-term growth play within the aerospace space.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing significant volatility and aggressive upside momentum as retail traders speculate on its high-profile private equity holdings like Anthropic, OpenAI, and SpaceX. While the community is debating the stock's massive premium over its net asset value and the impact of a six-month lockup period on the majority of existing shares, many are actively monitoring technical chart patterns and volume spikes to identify entry and exit points for what they perceive as a high-risk, high-reward trading opportunity.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

The SPERMWHALE token is sparking polarized debate as traders contrast its resilience against broader market volatility with concerns regarding its speculative nature. Community sentiment remains split between those observing quiet accumulation patterns and those skeptical of its long-term viability.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is rallying as shareholders celebrate a major leadership overhaul, including the appointment of Kevin Tang as CEO, which the community views as a critical step toward fiscal discipline and a potential sale of the company. Investors are actively discussing the removal of the previous CEO and the new leadership's decision to forgo traditional compensation, signaling to the market that the company is now positioning itself to maximize shareholder value.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is currently trending due to its aggressive global expansion, highlighted by live driverless robotaxi operations with Uber in the Middle East and new partnerships with Grab in Singapore. While the community is actively debating the company's long-term valuation and future revenue potential, investor sentiment remains mixed as they wait for more transparency from leadership regarding the 2026 growth roadmap.

The Estée Lauder Companies, Inc. engages in the manufacture of skin care, makeup, fragrance and hair care products. It sells products under Estée Lauder, Clinique, Origins, MAC, Bobbi Brown, La Mer, Jo Malone London, Aveda and Too Faced. The company was founded by Estee Lauder and Joseph Lauder in 1946 and is headquartered in New York, NY.

Estee Lauder Cos., Inc. - Ordinary Shares - Class A

Estee Lauder Cos. Inc

Este Lauder is trending following reports that it is nearing a merger deal with Puig, the parent company of Jean Paul Gaultier, sparking intense community debate over the potential impact on shareholder value. While some investors view the deal as a significant turnaround catalyst, others are actively questioning whether the merger will leave existing shareholders with diluted equity or meaningful long-term upside.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eledon Pharmaceuticals (NASDAQ:ELDN) Announces Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.10...

Eledon Pharmaceuticals Touts Tegoprubart Safety in BESTOW Kidney Transplant Data at Leerink Conference

Eledon Pharmaceuticals (NASDAQ:ELDN) used a presentation at the Leerink Partners Global Healthcare Conference to highlight what CEO David-Alexandre Gros described as a rapid expansion in clinical...

Eledon Pharmaceuticals (ELDN) to Release Quarterly Earnings on Thursday

Eledon Pharmaceuticals (NASDAQ:ELDN) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 19. (View Earnings Report at...

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance...

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Average Recommendation of "Hold" by Brokerages

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) has been given an average rating of "Hold" by the five research firms that are currently covering the stock, MarketBeat Ratings reports...

Eledon Pharmaceuticals Highlights BESTOW Data, Phase III Plans and FDA Timeline for Tego at Conference

Eledon Pharmaceuticals (NASDAQ:ELDN) executives discussed recent clinical results and upcoming regulatory plans for its investigational immunosuppressive therapy, referred to in the discussion as...

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Consensus Rating of "Hold" by Brokerages

Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) have received an average rating of "Hold" from the five research firms that are covering the stock, MarketBeat reports. One...

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Consensus Recommendation of "Hold" by Analysts

Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) have been given an average recommendation of "Hold" by the five research firms that are covering the company, Marketbeat...

The End of Shots? 5 Biotech Stocks Rethinking Diabetes

The End of Shots? 5 Biotech Stocks Rethinking Diabetes The End of Shots? 5 Biotech Stocks Rethinking Diabetes PR Newswire VANCOUVER, BC, Dec. 31, 2025 Issued on behalf of Avant Technologies Inc...

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Average Rating of "Hold" from Analysts

Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) have been given a consensus rating of "Hold" by the five brokerages that are covering the stock, MarketBeat Ratings reports. One...

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company, which engages in development of therapies to protect transplanted organs and prevent rejection. The firm also focuses on development of therapy to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L), a biological target with broad therapeutic potential. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.

ELDN
Eledon Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ELDN News

ELDNEledon Pharmaceuticals Inc